Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 1/20 | 0.66 |
| ▸ | BRAF | P15056 | 18/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.60 |
| ▸ | RAF1 | P04049 | 2/20 | 0.56 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.56 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.56 |
| ▸ | KDR | P35968 | 1/20 | 0.56 |
| ▸ | CSF1R | P07333 | 1/20 | 0.56 |
| ▸ | KIT | P10721 | 1/20 | 0.56 |
| ▸ | YES1 | P07947 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5448592 | 0.86 | BRAF (0.53) | KDM4EMAPTBRAFCYP2C9RAF1 | |
| SCHEMBL5004904 | 0.85 | BRAF (0.76) | BRAFCYP2C9RAF1YES1 | |
| SCHEMBL5442507 | 0.85 | BRAF (0.53) | BRAFCYP2C9RAF1YES1 | |
| SCHEMBL5442516 | 0.83 | BRAF (0.52) | BRAFCYP2C9RAF1YES1 | |
| SCHEMBL18196115 | 0.83 | BRAF (0.75) | BRAFCYP2C9CSF1R | |
| SCHEMBL1697866 | 0.82 | BRAF (0.55) | BRAFCYP2C9RAF1CSF1RKIT | |
| SCHEMBL1697890 | 0.81 | BRAF (0.59) | BRAFCYP2C9RAF1YES1 | |
| SCHEMBL1697892 | 0.81 | BRAF (0.56) | BRAFCYP2C9RAF1YES1 | |
| SCHEMBL5007890 | 0.81 | BRAF (0.71) | BRAFCYP2C9RAF1YES1 | |
| SCHEMBL5219474 | 0.81 | BRAF (0.75) | BRAFCYP2C9RAF1CSF1RKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070259849-A1 | Azine-Carboxamides as Anti-Cancer Agents | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| EP-1765790-A1 | AZINE-CARBOXAMIDES AS ANTI-CANCER AGENT | AstraZeneca AB (SE) | 2007-03-28 | — | — | EP | disclosed |
| WO-2006003378-A1 | AZINE-CARBOXAMIDES AS ANTI-CANCER AGENT | ASTRAZENECA AB (SE) | 2006-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259849-A1 | Azine-Carboxamides as Anti-Cancer Agents | ARAF, BRAF, RAF1 | KDM4E 521/4885MAPT 4743/4885BRAF 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.